Clinical trials: Hepatobiliary Disorders
Liver Disease
Quantitative Diagnosis of Fatty Liver by Dual Energy CT Technique
This study is proposed to explore the correlation between fatty content of fatty liver and the difference of CT attenuation value in men using dual-energy CT, and to set up a threshold for diagnosis of fatty liver.
- Trial name
- NCT00172705
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Acute Liver Disease
Causes, Complications and Outcomes of Severe Acute Liver Disease Cases Admitted to Intensive Care Units
Acute liver failure (ALF) is a potentially fatal complication of severe hepatic illness resulting from various causes. In a clinical setting, severe hepatic injury is usually recognized by the appearance of jaundice…
- Trial name
- NCT05879445
- Volunteers
- 200 people
- Sponsor
- Assiut University
Solid Tumor
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
This was an open-label, Phase 1/2, dose escalation and signal finding study of derazantinib administered to patients with advanced solid tumors (Part 1; Dose Escalation/Food-effect Cohorts) or with advanced solid tumors with FGFR…
- Trial name
- NCT01752920
- Testing
- Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range
- Where
- 12 sites in United States, Italy
- Volunteers
- 119 people
- Sponsor
- Basilea Pharmaceutica
Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease
Integrated Approaches for Identifying Molecular Targets in Liver Disease
To provide a framework for successful clinical trials testing novel targets for therapy in liver disease. To identify molecular and cellular drivers of liver disease to provide a molecular classification and study the…
- Conditions
- Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease, Steatohepatitis, Nonalcoholic, Steatohepatitis
- Trial name
- InLi (NCT03915002)
- Where
- United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Total Parenteral Nutrition-induced Cholestasis, Cholestasis
Compassionate Use of Omegaven in Children
This is a single-assignment study to evaluate whether Omegaven (IV fish oil) is effective at treating liver disease in children on long-term IV nutrition.
- Conditions
- Total Parenteral Nutrition-induced Cholestasis, Cholestasis, Short Bowel Syndrome, Gastroschisis
- Trial name
- NCT02370251
- Testing
- Omegaven
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Oklahoma
Childhood Obesity, NAFLD (Non-alcoholic Fatty Liver Disease)
Metabolic Syndrome and Gen-polymorphs Influence on Weightloss Among Children in Treatment for Overweight
Definition: the overall objective is to examine childhood obesity with focus on NAFLD and its treatment. Further, we aimed to investigate the impact of genetic variation on obesity.
- Conditions
- Childhood Obesity, NAFLD (Non-alcoholic Fatty Liver Disease), Hypertension, Hyperlipidemia
- Trial name
- NCT00823277
- Testing
- Chronic care multidisciplinary intervention of childhood obesity
- Where
- Denmark
- Volunteers
- 517 people, healthy volunteers welcome
- Sponsor
- Holbaek Sygehus
Type 2 Diabetes, Fatty Liver
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty…
- Trial name
- NCT06989723
- Testing
- Pioglitazone 15 MG [Actos], Empagliflozin 10 MG [Jardiance], Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
- Where
- South Korea
- Volunteers
- 120 people
- Sponsor
- Seoul National University Bundang Hospital
Overweight or Obesity
Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition
Soybean peptides are a mixture of active peptides obtained from the hydrolysis of soybean protein, which have biological activities such as antioxidant, blood pressure lowering, anti-fatigue and lipid lowering, etc.
- Trial name
- NCT04728399
- Testing
- Experimental group, Control group
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fangfang Zeng
Non-alcoholic Fatty Liver Disease
Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
The study is designed to assess the safety and efficacy of different doses and dosing regimens of Runihol, tablets, enteric coated, produced by "NTFF" POLYSAN" (Russia), in prevention of liver disease progression in patients with…
- Trial name
- NCT02930161
- Testing
- Runihol
- Where
- 3 sites in Russia
- Volunteers
- 35 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes
The purpose of this study is to evaluate whether exenatide is superior to insulin glargine (after 24 weeks) in reducing liver fat content (by MRS) in patients with newly diagnosed type 2 diabetes mellitus and concomitant…
- Trial name
- NCT02303730
- Testing
- Exenatide, insulin glargine
- Where
- 5 sites in China
- Volunteers
- 76 people
- Sponsor
- Fudan University
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate the effect of weight loss rate on liver steatosis, steatohepatitis, fibrosis and cardiovascular risk at different stages before and after bariatric surgery.
- Trial name
- NCT01828528
- Testing
- Sleeve gastrectomy
- Where
- Israel
- Volunteers
- 26 people
- Sponsor
- Sheba Medical Center
NAFLD
Effect of Mediterranean Diet on Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a clinical/biochemical condition associated with the metabolic syndrome. As the disease stems from excess calorie intake and lack of physical activity, the correction of unhealthy…
- Trial name
- Nutriepa (NCT01798719)
- Testing
- Low Glycemic Index Mediterranean Diet, General Advice
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
NAFLD
Resolution of Liver Fat in Non-alcoholic Fatty Liver Disease
The major adverse health consequences of obesity occur only when non-alcoholic fatty liver disease (NAFLD) also develops. NAFLD is characterized by abnormal hepatic accumulation of triglycerides and other lipids.
- Trial name
- NCT02558530
- Testing
- Low carbohydrate diet
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
The purpose of this study is to directly characterize the pharmacokinetic (PK) profiles of MGL-3196 and its major metabolite (MGL-3623) following administration of multiple oral doses (QD x 6 days) in subjects with varying…
- Conditions
- Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver
- Trial name
- NCT04643795
- Testing
- MGL-3196
- Where
- 3 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Madrigal Pharmaceuticals, Inc.
NAFLD, Type 2 Diabetes
Postprandial VLDL-triglyceride Metabolism in Type 2 Diabetes Patients With and Without NAFLD
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum from simple reversible hepatic steatosis to inflammation and fibrosis termed steatohepatitis (NASH).
- Trial name
- NCT05044130
- Testing
- High-fat mixed-meal tolerance test (HF-MMTT)
- Where
- Denmark
- Volunteers
- 17 people
- Sponsor
- University of Aarhus
Fatty Liver Disease
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat.
- Trial name
- NCT07214870
- Testing
- NNC4005-001
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Novo Nordisk A/S
Non-hepatobiliary Indications
EUS-Guided ATI and SWE in Individuals With Normal FibroScan
The goal of this observational study is to establish preliminary reference values for Endoscopic Ultrasound (EUS)-guided Attenuation Imaging (ATI) and Shear Wave Elastography (SWE) in adults undergoing diagnostic EUS for…
- Trial name
- EUS ATI&SWE (NCT07714941)
- Testing
- Endoscopic Ultrasound (EUS), EUS-guided Attenuation Imaging (ATI), EUS-Guided Shear Wave Elastography (SWE)
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Asian Institute of Gastroenterology, India
Carcinoma, Hepatocellular, Hepatitis C, Chronic
Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)
The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.
- Conditions
- Carcinoma, Hepatocellular, Hepatitis C, Chronic, Hepatitis B, Chronic, Cirrhosis, Liver
- Trial name
- dSEARCH (NCT05870969)
- Testing
- Liver cancer surveillance every 3 months, Liver cancer surveillance every 6 months, Liver cancer surveillance annually
- Where
- China
- Volunteers
- 20,000 people
- Sponsor
- Ruijin Hospital
Non Alcoholic Fatty Liver Disease
The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease
The Objective of This Study is Evaluating the Effect of oral β- glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver echogenicity and Enzymes in Non Alcoholic Fatty Liver Patients Treating with…
- Trial name
- NCT02178839
- Testing
- β- glucan, Maltodextrin
- Where
- Iran
- Volunteers
- 48 people
- Sponsor
- Urmia University of Medical Sciences
Short Bowel Syndrome, Intestinal Failure
Can SMOFlipid®, A Composite Parenteral Nutrition Lipid Emulsion, Prevent Progression Of Parenteral Nutrition Associated Liver Disease In Infants?
The aim of this study is to determine the feasibility of conducting a trial to examine the efficacy of an ω3FA (Omega-3 fatty acid) containing balanced lipid emulsion in the prevention of progression of PNALD in infants with…
- Conditions
- Short Bowel Syndrome, Intestinal Failure, Gastrointestinal Motility Disorder, Mucosal Enteropathy
- Trial name
- NCT00793195
- Testing
- Intralipid 20%, SMOFlipid 20%
- Where
- 5 sites in Canada
- Volunteers
- 24 people
- Sponsor
- The Hospital for Sick Children
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.